AXL: Anxiety Medication Management in MAT



Date & Location
Thursday, March 31, 2022, 12:00 PM - Sunday, March 30, 2025, 1:30 PM

Credits
AMA PRA Category 1 Credits™ (1.50 hours), ANCC Nursing Contact Hours (1.50 hours), CME-Designated Participation Credit (1.50 hours)

Overview

Review of:

  • Anxiety Disorders commonly co-occurring with OUD
  • Medication options for anxiety
  • Benzodiazepines for anxiety and MAT
  • Engaging patients in behavioral anxiety treatments
  • Sequencing dosage and medications

Presenter
Luke Archibald, MD

About our Presenter
Luke Archibald, MD, is an Addiction Psychiatrist and the Director of Addiction Services in the Department of Psychiatry at Dartmouth-Hitchcock, where he is an Assistant Professor of Psychiatry.  As medical director of the Dartmouth-Hitchcock Addiction Treatment Program, he oversees clinical services that include an Intensive Outpatient Program (IOP), medical visits for hundreds of individuals with substance use disorder, and the Doorway at Dartmouth-Hitchcock, the regional hub for the New Hampshire State Opioid Response (SOR) Doorway project.   

In addition, he serves as the program director for the Dartmouth-Hitchcock Addiction Psychiatry fellowship and is a core investigator of the Northeast Node of the Clinical Trials Network (CTN).  He is the site PI for CTN-0100: Optimizing Retention, Duration, and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD).  Dr. Archibald attended medical school at Columbia University College of Physicians and Surgeons.  He completed Psychiatry residency and Addiction Psychiatry fellowship at New York University.  Prior to joining Dartmouth-Hitchcock, he was the Director of the Addiction Division in the Department of Psychiatry at Bellevue Hospital in New York City.

Learning Outcome
At the conclusion of this Learning Collaborative, at least 75% of participants will be able to identify three evidence-based strategies that are designed to enhance the clinical team-based care of patients with substance or opioid use disorders treatment. 

Disclosure
The activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported NO financial relationship(s)* with ineligible companies**.

* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).

** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Bibliographic Material
See presentation for bibliographic references.


Accreditation

In support of improving patient care, Dartmouth Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

American Medical Association (AMA)
Dartmouth Health designates this Enduring Material for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center (ANCC)
Dartmouth Health designates this Enduring Material for a maximum of 1.50 ANCC contact hours.